Research group Drug Discovery

Smart Chemistry and AI for the Development of Safe Mosquito Repellents

kleurovergangen erlenmeyer in chemielab
Current mosquito repellents often have limited effectiveness and pose health and environmental concerns. In this project, newly identified molecules will be further optimized so that a safe and effective alternative can be developed.

Quick info

Status

Start-up phase

Start date

September 1, 2026

Duration

2.5 years

Program

SIA HBO-postdoc 2025-2030

Project leader

Stefan van de Rootselaar

 

Contact HAN

Dr. Dennis Löwik Dennis.Lowik@han.nl

Motivation

Mosquito- and tick-borne diseases pose an emerging threat and kill more than 700,000 people worldwide annually (source: WHO). Diseases such as dengue, West Nile virus, and Lyme disease are on the rise in the Northern Hemisphere. Some of these diseases were formerly considered primarily tropical, but due to climate change and globalization, the habitats of disease-transmitting vectors have expanded. As a result, these infections are now being reported increasingly often in temperate regions, including Europe and the Netherlands. The current standard for protection against bites, the repellent DEET, has limited efficacy against mosquitoes, damages plastics and fabrics, and raises health (skin irritation, neurotoxicity) and environmental concerns (aquatic toxicity).

Aim and method

In previous research, using advanced machine learning, chemical synthesis, and testing, HAN and TropIQ identified powerful lead repellent molecules with activity against a wide range of insects and ticks. In the new project, we will further optimize these molecules with the aim of producing one or more candidate molecules that are patentable, powerful, effective, and safe repellents, and suitable for subsequent product development.

Partners

TropIQ Health Sciences B.V.

Research group
 

Drug Discovery

A start-up project in the drug discovery phase has between a 5-10% chance of making it to the research phase. At that stage, the success rate is about 10% to make it to market. Thus, a start-up drug project has a very small chance of eventually reaching 'the shelves'. The researchers of this professorship contribute to drug development.